Metocure-T 50 Tablet ER is a combination antihypertensive medication containing Telmisartan 40 mg and Metoprolol Succinate 50 mg, formulated for extended-release administration. Telmisartan, an angiotensin II receptor blocker (ARB), selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure. Metoprolol Succinate, a beta-1 selective adrenergic blocker, reduces heart rate, myocardial contractility, and cardiac output, contributing to antihypertensive effects and improved cardiac function. This combination is indicated for the management of essential hypertension, particularly in patients requiring dual therapy for optimal blood pressure control. Metocure-T 50 Tablet ER offers the advantage of once-daily dosing due to its extended-release formulation, enhancing patient compliance. It is contraindicated in patients with severe bradycardia, cardiogenic shock, overt heart failure, or hypersensitivity to either component. Caution is advised in patients with hepatic or renal impairment, diabetes mellitus, or a history of bronchospastic diseases. Common adverse effects may include dizziness, fatigue, hypotension, and gastrointestinal disturbances. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy. Metocure-T 50 Tablet ER should be used under medical supervision with appropriate dose adjustments based on clinical response.